Publication:
Staphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab

No Thumbnail Available

Date

2021

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK

Research Projects

Organizational Units

Journal Issue

Abstract

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.

Description

Keywords

Abscess, chest wall, costochondritis, COVID-19, tocilizumab, SERIOUS INFECTIONS, RISK

Citation

URI

https://hdl.handle.net/11424/236693

Collections

Research Outputs